1. Home
  2. GRBK vs NAMS Comparison

GRBK vs NAMS Comparison

Compare GRBK & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRBK
  • NAMS
  • Stock Information
  • Founded
  • GRBK 2006
  • NAMS 2019
  • Country
  • GRBK United States
  • NAMS Netherlands
  • Employees
  • GRBK N/A
  • NAMS N/A
  • Industry
  • GRBK Homebuilding
  • NAMS Biotechnology: Pharmaceutical Preparations
  • Sector
  • GRBK Consumer Discretionary
  • NAMS Health Care
  • Exchange
  • GRBK Nasdaq
  • NAMS Nasdaq
  • Market Cap
  • GRBK 2.7B
  • NAMS 2.7B
  • IPO Year
  • GRBK N/A
  • NAMS N/A
  • Fundamental
  • Price
  • GRBK $59.84
  • NAMS $23.55
  • Analyst Decision
  • GRBK Hold
  • NAMS Strong Buy
  • Analyst Count
  • GRBK 3
  • NAMS 7
  • Target Price
  • GRBK $65.50
  • NAMS $38.17
  • AVG Volume (30 Days)
  • GRBK 327.9K
  • NAMS 581.4K
  • Earning Date
  • GRBK 02-27-2025
  • NAMS 02-06-2025
  • Dividend Yield
  • GRBK N/A
  • NAMS N/A
  • EPS Growth
  • GRBK 34.39
  • NAMS N/A
  • EPS
  • GRBK 7.71
  • NAMS N/A
  • Revenue
  • GRBK $1,982,011,000.00
  • NAMS $33,594,000.00
  • Revenue This Year
  • GRBK $19.54
  • NAMS $131.53
  • Revenue Next Year
  • GRBK $9.88
  • NAMS N/A
  • P/E Ratio
  • GRBK $7.77
  • NAMS N/A
  • Revenue Growth
  • GRBK 12.72
  • NAMS 78.77
  • 52 Week Low
  • GRBK $48.66
  • NAMS $15.19
  • 52 Week High
  • GRBK $84.66
  • NAMS $27.29
  • Technical
  • Relative Strength Index (RSI)
  • GRBK 49.86
  • NAMS 44.17
  • Support Level
  • GRBK $58.83
  • NAMS $22.53
  • Resistance Level
  • GRBK $61.19
  • NAMS $26.71
  • Average True Range (ATR)
  • GRBK 1.60
  • NAMS 0.97
  • MACD
  • GRBK 1.00
  • NAMS -0.45
  • Stochastic Oscillator
  • GRBK 79.28
  • NAMS 23.89

About GRBK Green Brick Partners Inc.

Green Brick Partners Inc is a homebuilding and land development company. It acquires and develops land, as well as provides land and construction financing to its controlled builders. The company has three reportable segments: builder operations central, builder operations southeast, and land development. The majority of the company's revenue is generated from the builder operations central segment which is entirely the operations of builders in Texas. The company is engaged in various aspects of the homebuilding process, including land acquisition and development, entitlements, design, construction, marketing, sales, and brand image creation. In addition to homebuilding, the company provides home financing services, such as mortgage and title, through its subsidiaries.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: